Prothena | PRTA

Stock Price
8.55
Daily Change
0.34 4.14%
Monthly
7.95%
Yearly
-57.94%
Q3 Forecast
8.48


Peers Price Chg Day Year Date
Acadia Pharmaceuticals 25.40 0.14 0.55% 61.07% Sep/08
Agios Pharmaceuticals 36.71 0.70 1.94% -16.44% Sep/08
ALKERMES 27.91 -2.03 -6.78% 3.91% Sep/08
Alnylam Pharmaceuticals 456.59 4.59 1.02% 80.36% Sep/08
Amgen 279.08 -4.56 -1.61% -14.35% Sep/08
Biogen 141.40 0.73 0.52% -29.02% Sep/08
BioMarin Pharmaceutical 55.72 -2.05 -3.55% -33.93% Sep/08
Exelixis 37.52 -0.36 -0.95% 49.18% Sep/08
Incyte 86.04 -0.60 -0.69% 38.19% Sep/08
Ionis Pharmaceuticals 60.21 -1.02 -1.67% 28.41% Sep/08
MacroGenics 1.80 -0.20 -10.00% -44.62% Sep/08
Neurocrine Biosciences 142.72 -1.38 -0.96% 18.77% Sep/08
Prothena 8.55 0.34 4.14% -57.94% Sep/05
Ultragenyx Pharmaceutical 31.75 -0.07 -0.22% -42.52% Sep/08
Regeneron Pharmaceuticals 554.68 -18.70 -3.26% -51.51% Sep/08
Vertex Pharmaceuticals 392.77 -3.35 -0.85% -16.57% Sep/08

Indexes Price Day Year Date
USND 21810 109.65 0.51% 29.17% Sep/08
US2000 2387 -3.75 -0.16% 13.80% Sep/08

Prothena traded at $8.55 this Friday September 5th, increasing $0.34 or 4.14 percent since the previous trading session. Looking back, over the last four weeks, Prothena gained 7.95 percent. Over the last 12 months, its price fell by 57.94 percent. Looking ahead, we forecast Prothena to be priced at 8.48 by the end of this quarter and at 8.28 in one year, according to Trading Economics global macro models projections and analysts expectations.

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.